An observational study in Neoplasm Metastasis, Locoregional Neoplasm and Advanced Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Context: In people concerned by serious illness, how to anticipate the aggravation of the disease according to the patient's preferences is a challenging clinical question and an ethical key-issue to improve end-of-life care and quality of dying in France. When end of life decision occurs, many patients can no longer express themselves and advance directives do not seem to be appropriate for many patients despite the current strong incentives to write them, reinforced by the 2016 Claeys Leonetti.
The "End-of-Life Discussions" and "Advance care planning" programs developed in the United States have shown a positive impact on the aggressiveness of end-of-life care. The implementation in France of these programs has not yet been consolidated despite a first recommendation for "Planification des soins futurs", published by the French Health Authority(HAS). Inspired by the definition given in the later document, investigators propose the acronym DDA, for the Discussions Dedicated to Anticipate wishes and preferences in the event of Aggravation, defined as the dynamic and evolving process of reflection and communication between the patient, his relatives and healthcare professionals, allowing him to address his preferences and wishes regarding his care and treatment
The objective of this observational study is to characterize, in a population of patients with advanced cancer, the profile of those who take up a proposal for Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA) and who engage in the discussion process. Secondary objectives are to
Method: investigators designed a mixed, quantitative and qualitative prospective, monocenter methodology to evaluate how patients take up a proposal of DDA. This proposal consists in 2 interviews: the first one is dedicated to the assessment of the patient's wishes in terms of information and participation in decision-making (API questionnaire) and to the assessment of the degree of anxiety and depression (HADS questionnaire) (E1). The second one is conducted 1 to 4 weeks later and consists in offering and initiating DDA (E2).
Quantitative outcome evaluated will be:
Thanks to this study investigators expect to gather some data on the desire and feelings of cancer patients to engage in a DDA process and possibly formalize their end-of-life preferences, the impact of DDAs on care pathway indicators and the psychological effect for the patient with severe disease to project himself in advance into aggravation.
These expected results will provide a better understanding of the process of anticipating end-of-life situations, which is needed to improve quality of care and end-of-life conditions.
In the United States, the respect of patient's autonomy was early considered in 1990 by the Patient Self Determination Act, which stated that all persons entering a publicly funded health care facility had to be informed of their rights to formulate living wills. Meanwhile, tools have been developed to evaluate patients' expectations regarding information and participation in medical decision-making, e.g. the Autonomy Preference Index (API), initially conceived for general practice [Ende J 1989]. Since then, "End-of-Life Discussions" and "Advance care planning" programs have shown a positive impact on the aggressiveness of end-of-life care [Wright 2008, Mack 2012, Dow 2009]. However, some other studies have also suggested that patients in situations of real worsening would be less likely to seek prognostic information and could be unsettled by these programs [Michael 2013; Maciejewski 2013].
In France, the right to designate a "durable power of attorney for health care" (fr. "Personne de Confiance" (PC)) dates back to 2002, and the right to formulate "living wills" (fr. "Directives Anticipées" (DA)) concerning end-of-life care was first introduced by law in 2005 and their importance was reinforced in 2016. Recently, investigators established the validity and reliability of the French version of the API among patients with incurable cancer and in primary care setting. They found high patient expectations for information on their health status but a more variable desire to be involved in medical decisions. Three supplementary items were added specifically to evaluate incurable cancer patients' attitude towards anticipating their preference of care in the event of worsening health status. These suggested that anticipating may be for patients a specific dimension, not correlated with those of information and participation in decision making. Other French surveys show the low appropriation of PC and DA and suggest that DAs are not necessarily appropriate for all patients, despite the strong current incentives to write them.
The implementation in France of "Advance care planning" programs has not yet been consolidated despite a first recommendation for "Planification des soins futurs", published by the HAS (French Health Authority). Inspired by the definition given in the later document, we propose the acronym DDA, for the Discussions Dedicated to Anticipate wishes and preferences in the event of Aggravation, defined as the dynamic and evolving process of reflection and communication between the patient, his relatives and healthcare professionals, allowing him to address his preferences and wishes regarding his care and treatment.
Considering that the strictly numerical objective of writing living wills or designating a PC is not a relevant indicator of quality of care, investigators rather aim to get a better understanding of the process of DDA, assuming that this process would contribute to improve quality of care at the end-of-life.
The objective of this observational study is to characterize, in a population of patients with advanced cancer, the profile of those who take up a proposal for Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA) and who engage in the discussion process. Secondary objectives are to 1) evaluate the aggressiveness of end-of-life care in the group of patients who died 1 year after their inclusion, depending on their engagement in DDA occurs and whether or not their preferences are formalized; and 2) evaluate the subjective effects of the DDA with the patient and the investigating professionals, through qualitative approach by a clinical psychologist.
For each of 240 patients with advanced metastatic cancer recruited in the oncology department of a university hospital, the mixed method of evaluation consists in :
Quantitative outcomes evaluated were inspired by the results of the consensus work published by Sudore and al, on outcomes design to evaluate success of Advance Care Planning. There will be:
3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.
This study's enrollment of 71 is below the median of 121 across 594 observational studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients population in medical care for advance cancer in oncology or pneumology, for which the aim is not the cure of the disease, but rather longer survival or quality of life maintenance, whose lifespan expectation is approximately higher than a year.
Exclusion Criteria:
interview 2
part of interview 1
part of interview 1
Documentation by a physician of patient's care preferences/values 6 months after E2 interview
Rate of patients for whom this documentation by a physician is found in hospital electronic medical record
Time frame: 7 months
Patient has decided and documented his/her choice on a surrogate decision maker
Rate of patients who have designated their surrogate on the appropriate form, signed by both the patient and surrogate
Time frame: 7 months
Patient has written advanced directives
Rate of patients who either declare having written advanced directives at E2 OR at telephone interview 2 months after E2 OR for whom advances directives are documented in their hospital electronic medical record 6 months after E2
Time frame: 7 months
Patient has discussed values and care preferences with the surrogate
Rate of patients who declare having discussed this with their surrogate, as investigated at the E2 interview
Time frame: 7 months
Anxiety generated by the E2 interview
Patient-reported anxiety, on a numerical scale (0 no anxiety-10 maximal imaginable anxiety)
Time frame: at the end of E2 (4 weeks)
REASSURING
answer "YES" to the question: "Do you think this interview and discussion was REASSURING?
Time frame: at the end of E2 (4 weeks)
NECESSITY
answer "YES" to the question: "Do you think this interview and discussion was NECESSARY?
Time frame: at the end of E2 (4 weeks)
USEFULNESS
answer "YES" to the question: "Do you think this interview and discussion was USEFUL?
Time frame: at the end of E2 (4 weeks)
Complete initiation of DDA
Rate of patients who completed the E2 interview until its end (with all data specified collected)
Time frame: at the end of E2 (4 weeks)
Time from 1st intervention of the palliative care team to death <30 days
Evaluated only in decedents (i.e early access to palliative care)
Time frame: 12 months follow-up
Proportion of patients who received chemotherapy in the last 14 days of life
Evaluated only in decedents
Time frame: 12 months follow-up
Proportion of patients who visited ≥2 times emergency room in the last month of life
Evaluated only in decedents
Time frame: 12 months follow-up
Proportion of patients admitted at least once to intensive care in the last month
Evaluated only in decedents
Time frame: 12 months follow-up
Time from transfer to Palliative Care Inpatient Unit (if applicable) to death <= 3 days
Evaluated only in decedents, (i.e. late transfer to Palliative Care Inpatient Unit)
Time frame: 12 months follow-up
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris